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Abstract: Pancreatic ductal adenocarcinoma (PDAC) has long been associated with low survival rates.
A lack of accurate diagnostic tests and limited treatment options contribute to the poor prognosis
of PDAC. Radioimmunotherapy using α- or β-emitting radionuclides has been identified as a
potential treatment for PDAC. By harnessing the cytotoxicity of α or β particles, radioimmunotherapy
may overcome the anatomic and physiological factors which traditionally make PDAC resistant
to most conventional treatments. Appropriate selection of target receptors and the development
of selective and cytotoxic radioimmunoconjugates are needed to achieve the desired results of
radioimmunotherapy. The aim of this review is to examine the growing preclinical and clinical trial
evidence regarding the application of α and β radioimmunotherapy for the treatment of PDAC.
A systematic search of MEDLINE® and Scopus databases was performed to identify 34 relevant
studies conducted on α or β radioimmunotherapy of PDAC. Preclinical results demonstrated α and β
radioimmunotherapy provided effective tumour control. Clinical studies were limited to investigating
β radioimmunotherapy only. Phase I and II trials observed disease control rates of 11.2%–57.9%,
with synergistic effects noted for combination therapies. Further developments and optimisation of
treatment regimens are needed to improve the clinical relevance of α and β radioimmunotherapy
in PDAC.
Keywords: pancreatic cancer; radioimmunotherapy; radiolabelled antibodies; alpha particles; beta
particles; targeted therapy
1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with an unmet
clinical demand. Despite advances in conventional therapies, the five-year survival rate of PDAC has
remained largely unchanged over recent decades and sits at 9.8% in Australia [1]. Surgery remains
the only curative treatment option for PDAC. However, its application is limited to patients with
locally resectable disease only (approximately 10%–20% of cases) [2]. Post-surgery, hepatic metastasis,
local recurrence and peritoneal dissemination are commonly observed and thought to stem from
undetectable or micro-metastases [3]. For patients ineligible for surgery, first-line treatment includes
the chemotherapy regimen FOLFIRINOX (a combination of fluorouracil, leucovorin, irinotecan,
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and oxaliplatin) or gemcitabine. External beam radiotherapy may also be delivered in some cases.
Despite evidence demonstrating that these treatments can extend patient survival, they are not
curative [4]. Several anatomical and physiological factors contribute to the lack of curative treatments
for PDAC including the unfavourable location of the pancreatic vasculature, which complicates surgical
resections [5]; the cellular heterogeneity of the pancreas, which limits the effectiveness of using a single
treatment type only [6,7]; the stromal barrier and high interstitial pressure within the pancreas, which
restrict the entry of intravenous substances including chemotherapy agents [8,9]; and the hypoxic
nature of PDAC cells, which reduces the efficacy of radiation treatment [10].
To overcome these barriers, there has been considerable research into new PDAC therapies, such
as radioimmunotherapy (RIT). In RIT, α- or β-emitting radionuclides are bound to a monoclonal
antibody (mAb) or antibody fragment using a chelator to form a radioimmunoconjugate (Figure 1).
These radioimmunoconjugates systemically bind to cancerous cells, delivering a cytotoxic radiation
dose directly to the tumours. The level of damage induced in the targeted cells is largely dependent on
the radionuclide selected. Whilst β-emitting radionuclides have been more widely used, α-emitting
radionuclides are considered superior, particularly for the treatment of micro-metastases [11]. This is
primarily due to the high linear energy transfer (LET) of the α particle allowing for dense ionisation
damage of the DNA. Consequently, only one direct α particle hit to a cell nucleus is needed to cause
complex double-strand DNA breaks and kill an isolated or single cell, even in hypoxic conditions [11].
Several β particle hits are needed to achieve a similar level of cell kill, with a single β particle hit
causing repairable damage only [12]. As β particles have low LET, the majority of damage is caused
through the production of free radicals, which require a normoxic environment [13,14]. Despite β
particles inducing some cell damage, the cytotoxicity of the β particle is insufficient to overcome the
hypoxic environment of most solid tumours. However, the longer range and enhanced cross-fire effect
of the β particle is advantageous for targeting larger primary tumours. Whilst α particles also induce a
cross-fire effect, it is less effective than a β particle, making the α particle more suited for targeting
micro-metastases [11,15].
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The different physical properties of α- and β-emitting radionuclides provide both α and β RIT
with their own advantages and disadvantages for treating PDAC. With growing research into both RIT
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types, the aim of this review is to evaluate the current preclinical and clinical trial evidence of α and β
RIT for the treatment of PDAC. This paper will review the targets and radionuclides investigated in
RIT of PDAC, then analyse the studies with respect to study type (in vitro, in vivo and clinical trials)
to identify the current status and future directions of research into RIT of PDAC.
2. Methods
The present review was conducted by searching MEDLINE® and Scopus databases using the
key terms in Table A1. The search was last conducted in August 2019. Additional studies were also
identified by pearling recent articles. The World Health Organisation’s International Clinical Trials
Registry and ClinicalTrials.gov were also searched using the key terms “radioimmunotherapy” and
“pancreatic cancer” to identify any ongoing or unpublished clinical trials. Duplicate records were
removed, and the remaining studies were independently reviewed by two reviewers for inclusion.
Studies were excluded if they were reviews, abstract or conference papers, did not investigate RIT or
PDAC and were diagnostic in nature. Any disagreements between reviewers were evaluated by a third
reviewer. Only full original research papers published since 2000, written in English, and explicitly
investigating RIT of PDAC were included in this review. In total, the search and pearling retrieved
238 records—of which, 34 were included in this review following a screening process (Figure A1). Of
the retrieved articles, 8 related solely to α RIT and 25 related to β RIT, with one article investigating
both approaches.
Whilst the literature was systematically retrieved using the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines [16], a systematic analysis was not
possible due to the high heterogeneity of data across the studies. Instead, identified papers were read
in full, with relevant data extracted and tabulated for ease of understanding. The country of origin and
year of publication were analysed for both α and β RIT studies as well as the radionuclides and targets
used. Finally, all studies were analysed according to the study type—in vitro, in vivo and clinical
trials—to allow for a more comprehensive review.
3. Results and Discussion
3.1. Literature Analysis
The majority of research into RIT for PDAC has originated from the United States of America
(USA), followed by Australia and Japan (Figure 2). Research into α RIT in PDAC has mostly originated
from the USA and Australia, with four original research papers published from each country. Since
2000, there has been a steady increase in β RIT publications whilst publications on α RIT in PDAC
have been more sporadic (Figure 3). There has been a gradual increase in α RIT publications since
2017, corresponding to increasing interest in targeted α therapies in general.
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Figure 2. Distribution of publications of radioimmunotherapy (RIT) in pancreatic ductal
adenocarcinoma (PDAC) by country of origin.
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Figure 3. Cumulative distribution of identified publications RIT for PDAC since 2000.
3.2. Radionuclides
Several factors can influence the choice of radionuclide used in RIT, including half-life, range, LET
and particle emission. Each of these physical properties has potential to affect the cytotoxicity and
tolerability of the radioimmunoconjugate. For example, the half-life of the radionuclide should be
sufficient to allow for tumour diffusion but not overly long to cause significant radiation damage to
normal tissues [17]. Within the retrieved articles, three β-emitting radionuclides (Yttrium-90 (90Y),
Lutetium-177 (177Lu) and Iodine-131 (131I)) and three α-emitting radionuclides (Actinium-225 (225Ac),
Bismuth-213 (213Bi) and Lead-212 (212Pb)) have been investigated. The physical properties of the
investigated radionuclides all differ as shown in Table 1, where the maximum energy and range in
water were calculated using The Stopping and Range of Ions in Matter (SRIM) software (Ziegler 2013).
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Table 1. Physical characteristics of α- and β-emitting radionuclides used for RIT of PDAC.
Half-Life LET in Water(keV/µm)
Maximum
Energy (MeV)
Maximum Range
in Water (µm)
Number of PANC-1
Cells Traversed *
A emitters Maximum
225Ac 9.92 d 102 8.4 82.2 3.9
213Bi 45.6 m 102 8.4 82.2 3.9
212Pb 10.6 h 99.4 8.8 88.5 4.2
B emitters Average
90Y 2.67 d 2.00 2.28 11400 570
177Lu 6.65 d 0.28 0.498 1800 125
131I 8.02 d 0.20 0.606 3032 202
* Calculated using the average cell diameter of a PANC-1 pancreatic cancer cell line of 20 µm. LET, linear
energy transfer.
Due to the difference in range of α and β particles, there is a trade off between homogeneity of
tumour dose and radiation-induced normal tissue toxicities. As β particles are capable of traversing
over hundreds of PDAC cells, as shown in Table 1, they have an enhanced cross-fire effect compared
to α particles, whereby nearby non-targeted cells are also irradiated [18]. This results in a more
homogeneous distribution of radiation dose to the tumour. However, it can also increase radiation
dose to normal tissues and the likelihood of side effects. The shorter range α particles are capable of
only cross-firing to approximately four neighbouring cells, limiting damage to nearby normal cells [11].
The radiation dose delivered to the tumour by the α particles is more heterogenous in nature, with
non-irradiated tumour cells continuing to grow, providing one of the major drawbacks of α RIT [15].
The nature of decay of between α and β emitters provides another area of difference. Generally,
α emitters undergo a chain of radioactive decay resulting in the formation of several daughter
radionuclides. These daughter radionuclides can present additional challenges and need to be
appropriately contained when used in RIT to prevent unnecessary damage to normal tissues. Whilst
there are less safety implications following β decay, the relative biological effectiveness (RBE) of an α
particle is over 100 times greater than that of a β particle. As RBE refers to the amount of radiation
needed to induce the same biological effect, this indicates the superior cytotoxicity of the α particle [19].
Given methods can be developed to overcome these safety implications, many would argue that
the impressive cytotoxicity of the α particle makes RIT using α-emitting radionuclides the preferred
therapeutic approach compared to β RIT [11].
Off-target or indirect radiation effects may also be induced by bothα- andβ-emitting radionuclides
and have potential to affect the safety and efficacy of RIT. The primary off-target effects considered
in radiation therapies are the bystander and abscopal effects. The bystander effect refers to the
radiation effects induced in non-irradiated cells as a result of cellular signalling from nearby, irradiated
cells [20]. The level of bystander effect induced is related to dose, dose rate and LET of the radiation
delivered [20]. Most simply, the bystander effect is considered strongest at low LET (e.g.,βparticles) [21].
The relationship between high LET radiation, such as α particles, radiation dose and bystander effects,
is more complex. Boyd et al. [22] suggests there is a U-shaped relationship between radiation dose
and the bystander effect when high LET radiation is used. Further research into the bystander effect
in RIT is needed to elucidate this finding. A distant bystander effect, known as the abscopal effect,
is also yet to be fully evaluated in RIT. The abscopal effect refers to the immune-mediated biological
effects observed in distant, non-irradiated cells [20]. Although considered a rare phenomenon, the
abscopal effect can cause shrinkage of non-irradiated tumour cells and its presence may also be related
to the radiation dose or LET [23]. Despite limited research into the off-target effects of RIT specifically,
it remains important to consider their potential to enhance damage to both normal and cancerous cells
when developing clinically relevant RIT regimens.
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3.3. Targets
An ideal RIT target should be selected based on its expression profile on cancerous and normal
cells, low blood circulation and high affinity to the intended radioimmunoconjugate. Across the
analysed articles, a total of 16 different targets have been investigated. Many of these targets play
some role in the progression of cancer and are known to be aberrantly overexpressed in PDAC. Table 2
summarises the expression of these targets (excluding intracellular targets such as single strand DNA
and La ribonucleoprotein) in PDAC tissues using immunohistochemical (IHC) staining. For those
targets where IHC data is not available, flow cytometry or immunoreactivity data in PDAC cell lines is
presented instead. Whilst a RIT target should ideally be overexpressed in cancerous cells, but have
minimal to no expression in normal cells, the target expression in normal human tissues is rarely
presented. As such, this data is not included in Table 2.
Table 2. Expression of RIT targets in PDAC.
Target Antibody
Expression in
PDAC Cells or
Tissues
Measurement
Type References
B7-H3 Anti-B7-H3 (1027) 88.2% (60/68) IHC Loos et al. [24]
CA19-9 5B1CA19-9
77.7% (7/9)
90.7% (39/43)
IHC
IHC
Viola-Villegas et al.
[25]
Shi et al. [26]
CD147 MEM-M6/1 andHIM6 combination 87.2% (34/39) IHC Riethdorf et al. [27]
CEA Anti-CEA 89.2% (223/250) IHC Yamaguchi et al.[28]
CENT 1 Anti-CENT 1 50.0% (10/20) IHC Jiao et al. [29]
EGFR Anti-EGFR (H11) 88.5% (92/104) IHC Al-Ejeh et al. [6]
Ferritin Bz-DTPA-AMB8LK 52% (CAPAN-1cells) Immunoreactivity Sabbah et al. [30]
HER 2 Anti-HER 2 59.9% (124/207) IHC Harder et al. [31]
Integrin avß5 14C5 100 (4/4) IHC Vervoort et al. [32]
Integrin α6β4
ITGA6B4
55% (range:
13.1–91.0% across
four cell lines)
Flow cytometry Aung et al. [33]
439-9B 92.0% (104/113) IHC Cruz-Monserrate etal. [34]
MUC1 C595MA5
90.5% (48/53)
100% (43/43)
IHC
IHC
Qu et al. [35]
Shi et al. [26]
MUC1/MUC5AC PAM4 79.1% (34/43) IHC Shi et al. [26]
PDGFR-β Anti-PDGFR-β 100% (5/5) IHC Hwang et al. [36]
TRFC Anti-TFRC (Ber-T9) 80.4% (41/51) IHC Ryschich et al. [13]
uPA/uPAR PAI2 87% (26/30) IHC Qu et al. [37]
CA19-9: carbohydrate antigen 19.9, CEA: carcinoembryonic antigen, CENT 1: centrin 1, EGFR: epidermal
growth factor receptor, HER 2: human epidermal growth factor receptor 2, MUC1: mucin 1, MUC5AC: mucin
5AC, PDGFR- β: platelet-derived growth factor receptor beta, TRFC: transferrin receptor, uPA/uPAR: urokinase
plasminogen activator/urokinase plasminogen activator receptor, PAI2: plasminogen activator inhibitor 2, and
IHC: immunohistochemistry.
Of the 15 targets in this review, only mucin 1 (MUC1), carbohydrate antigen 19.9 (CA19-9) and
centrin 1 (CENT1) have been investigated in bothα andβRIT for PDAC. In the healthy pancreas, MUC1
is expressed by both acinar and ductal cells and has a role in cell differentiation and signalling [38].
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However, in cancerous cells, MUC1 is aberrantly glycosylated and expressed allowing for targeting
of cancer-specific MUC1 epitopes (MUC1-CE) [38]. The exact role of MUC1 in cancer progression
is unknown, although it is believed to have anti-adhesion properties which allow cells to evade
immunological defences [38].
CA19-9, a tumour-associated antigen, is considered the most accurate serum biomarker for
PDAC [39]. As CA19-9 levels are abnormally raised in both malignant and benign pancreatic
conditions, the use of this biomarker is predominantly restricted to monitoring tumour growth and
treatment success in PDAC patients [40,41]. Whilst CA19-9 does have value as a biomarker, the utility
of this antigen as a RIT target remains unclear. Recent research has suggested that CA19-9 is involved
in the pathogenesis of PDAC and pancreatitis with increased expression in these diseases [42]. Despite
CA19-9 being an appealing therapeutic target, the increased expression in pancreatitis and known
free circulation of CA19-9 may lead to unwanted targeting of benign pancreatic tissue and normal
tissues throughout the body [43]. The expression of CA19-9 may be less problematic as a diagnostic
target where lower energy radionuclides are used [43]. Regardless, further research is warranted to
determine the full potential of CA19-9 as a RIT target.
CENT1 is a calcium-binding protein belonging to the cancer testis antigen group. Primarily
CENT1 is involved in the mitosis and meiosis of normal cells [29]. Similar to MUC1, the expression
of CENT1 is increased by approximately 25-fold in PDAC tissues compared to normal tissues [29].
Whilst the role of CENT1 in PDAC is not yet clear, its expression profile and location in centromeres
suggests it may be a valuable RIT target for PDAC [29,44].
3.4. In Vitro Studies
In vitro studies are commonly performed as preliminary experiments to evaluate the feasibility of
a therapeutic approach. Whilst in vitro studies are unable to fully assess the biokinetics of an agent and
lack replication to the tumour micro-environment, they provide a cost-effective approach to obtaining
baseline data without needing animal models [45]. Of the investigated articles, 13 included an in vitro
study component. The number of studies investigating α (n = 6) and β RIT (n = 7) were near equal
for this component. The results of the in vitro studies are summarised in Table 3. Only studies with
quantitative in vitro results which extend beyond flow cytometry analyses for receptor expression are
presented in this Table. The cell survival results of selected studies are illustrated in Figure 4.
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Table 3. Summary of the in vitro studies investigating α and β RIT approaches for the treatment of PDAC.
Study/Objective Target RIC Dissociation Constant ±SEM (nmol/L) Cell Binding (%) Survival Using RIC
Survival Using
Non-Specific Control
RIC
Apoptotic Cells Or
γ-H2AX Foci (% ±
SEM Where Available)
A-RIT Studies
Kasten et al. [46]
Cell binding B7-H3
212Pb-376.96
Adherent cells: 9.0 ± 1.1
CIC: 21.7 ± 0.7
Internalisation:
Adherent cells: 44
CIC: 40
Measure: IC50 ± SEM
Adherent cells: 41 ± 14
CIC: 26 ± 17
Measure: IC50 ± SEM
Adherent cells: 120 ± 12
CIC cells: 180 ± 150
Not investigated
Qu et al. [37]
In vitro
cytotoxicity
uPA/uPAR 213Bi-PAI2 Not investigated Not investigated
Measure: activity for 37% cell
survival (kBq)
CFPAC-1: 133
CAPAN-1 185
PANC-1: 170
At 370 kBq:
5%–10% cell survival
Measure: activity for
37% cell survival
2.2–2.7 MBq for all cell
lines
At 370 kBq:
90%–95% cell survival
Measure: apoptotic cells
At 24 h:
CFPAC-1: 92
CAPAN-1: 87
PANC-1: 90
Control RIC: <5%
Qu et al. [47]
In vitro
cytotoxicity
MUC1 213Bi-CHX.A”-C595 Not investigated Not investigated Not investigated Not investigated
Measure: apoptotic cells
At 48 h:
CAPAN: 73 ± 2.6
PANC-1: 78 ± 1.8
CFPAC-1: 81 ± 3.0
Control RIC: <12 ± 3.0
Qu et al. [35]
In vitro
cytotoxicity
MUC1 213Bi-cDTPA-C595 Not investigated Not investigated
Measure: activity for 37% cell
survival (kBq)
CAPAN-1: 167
CFPAC-1: 141
PANC-1: 159
At 370 kBq:
5%–10% cell survival
Measure: activity for
37% cell survival (MBq)
2.2–2.6 for all cell lines
At 370 kBq:
90–95% cell survival
(control RIC)
>95% cell survival
(conjugated mAb or
intact mAb only)
Measure: Combined cell
counts
4 h: 11
8 h: 18
12 h: 42
24 h: 87
48 h: 92
72 h: 81
Control RIC: <15% at all
time points
B-RIT Studies
Sugyo et al. [48]
Cell binding CD147
111In-059-053 (diagnostic
agent to 90Y-059-053)
Intact 059-053: 0.35
CHX-A”-DTPA-059-053: 0.99
111In-059-053: 51 in BxPC-3 cells Not investigated Not investigated Not investigated
Aghevlian et al.
[49]
In vitro
cytotoxicity
EGFR 177Lu-MCP-panitumumab Not investigated
RIC: 4.16 ± 0.17
RIC with excess mAB: 0.35 ± 0.01
Control RIC with excess mAB: 1.21
± 0.18
Measure: clonogenic survival of
treated cells compared to
untreated controls
1.2 MBq RIC: 7.4-fold decrease
0.6 Mbq RIC: 9.0-fold decrease
0.3 MBq RIC: 1.9-fold decrease
Not investigated
Measure: γ-H2AX foci
1.2 MBq RIC: 3.8-fold
increase in density vs.
untreated controls
Al-Ejeh et al. [6]
In vitro
cytotoxicity
EGFR 177Lu-anti-EGFR Not investigated Not investigated
Measure: clonogenic survival
Triple combination therapy
(RIT, Chk1i and gemcitabine)
significantly reduced
clonogenic survival vs.
untreated controls
Quantitative results not
presented
Not investigated at an
in vitro level
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Table 3. Cont.
Study/Objective Target RIC Dissociation Constant ±SEM (nmol/L) Cell Binding (%) Survival Using RIC
Survival Using
Non-Specific Control
RIC
Apoptotic Cells Or
γ-H2AX Foci (% ±
SEM Where Available)
Sabbah et al. [30]
Cell binding Ferritin
111In- and 90Y-labelled
Bz-DTPA-AMB8LK,
Bz-CHX-AU-DTPA-AMB8LK
and Bz-DOTA-AMB8LK.
Not investigated
111In-DTPA-AMB8LK: 52
111In-CHX-A”-DTPA-AMB8LK: 43
111In-DOTA-AMB8LK: 24
Not investigated Not investigated Not investigated
Vervoort et al. [32]
Cell binding Integrin avß5
125I-14C5,
111In-DOTA-
14C5 and
111In-DTPA-14C5
125I-14C5: 0.11 ± 0.01
111In-DTPA-14C5: 0.24 ± 0.02
111In-DOTA-14C5: 0.11 ± 0.03
Control RIC: no specific
binding
Internalisation at 24 h
125I-14C5: 6.93 ± 0.88
111In-DOTA-
14C5: 49.44 ± 0.75
111In-DTPA-14C5: 36.66 ± 1.42
Not investigated Not investigated Not investigated
Aung et al. [50]
In vitro
cytotoxicity
Integrin α6β4 90Y-ITGA6B4 Not investigated Not investigated
Measure: colony formation at
24 h
RIC and BEZ235: 90.9%
reduction of PE vs. control
RIC only: 52.5% reduction of
PE vs. control
Included in previous
column
Measure: γ-H2AX
positive cells (mean ±
SD) at Day 3
RIC and BEZ235:
19.3 ± 7.0
RIC only: 12.7 ± 4.7
BEZ235 only: 4.0 ± 2.2
Control: 2.3 ± 1.2
Sugyo et al. [51]
Cell binding Transferrin
111In-labelled TSP-A01,
DOTA-TSP-A01, TSP-A02
and DOTA-TSP-A02
(diagnostic agents for
90Y-TSP-A01)
111In-TSP-A01: 0.22
111In-DOTA-TSP-A01: 0.28
111In-TSP-A02: 0.17
111In-DOTA-TSP-A02: 0.22
Immunoreactive fraction:
111In-TSP-A01 and
111In-DOTA-TSP-A02: 1.0
Not investigated Not investigated Not investigated
RIC: radioimmunoconjugate, SEM: standard error measurement, CIC: cancer initiating cells, IC50: half maximal inhibitory concentration, mAb: monoclonal antibody, MCP: metal chelating
polymer, Chk1i: checkpoint kinase 1 inhibitor, and PE: plating efficiency.
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The objective of the in vitro studies differed between the therapeutic approaches used in the
literature. In α RIT, in vitro studies were primarily used to evaluate the inhibition and cytotoxicity
of the radioimmunoconjugates whilst in vitro β RIT studies typically assessed cell binding of the
radioimmunoconjugate. Given α-emitting radionuclides are expensive and supplies are limited, it
is likely to be more cost effective to investigate the cytotoxicity of α immunoconjugates at a cellular
level prior to advancing to animal models [52]. As β-emitting radionuclides are more readily available,
there is greater flexibility to investigate the inhibitory effects of these conjugates in animal models
where the overall conjugate effect can be better investigated. Currently there are no studies comparing
α and β RIT at a cellular level.
All α RIT studies demonstrated effective cytotoxicity or inhibitory effects of the
radioimmunoconjugate at the in vitro level compared to non-specific isotype control
radioimmunoconjugates. The overall dose needed for 37% of cell survival (D0) and the percentage of
apoptosis was similar between Qu et al. [37] and Qu et al. [35] despite investigating different targets and
213Bi-labelled conjugates. Across the same three PDAC cell lines, Qu et al. [37] demonstrated the D0
ranged from 133 to 185 kBq when targeting the urokinase plasminogen activator/urokinase plasminogen
activator receptor (uPA/uPAR). In comparison, Qu et al. [35] showed the D0 varied from 141 to 167
kBq when targeting cancer-specific MUC1 epitopes (MUC1-CE). Similarly, the combined percentage
of apoptotic cells at 24 h was 90% when targeting uPA/uPAR and 87% when targeting MUC1-CE
with the test radioimmunoconjugates [35,37]. When compared to the control radioimmunoconjugate
which produced apoptosis in <15% (MUC1-CE) and 5% (uPA/uPAR) of cells, it can be concluded the
therapeutic effect of the test radioimmunoconjugate is due to the overall conjugate, rather than the
general radiation effects of 213Bi. These studies highlight the potential of α RIT to provide a targeted
therapeutic effect.
Whilst in vitro studies are typically limited by not accounting for tumour physiology, replication
to the tumour micro-environment can be enhanced by using 3D tumour spheroids. Of the retrieved
articles, only Qu et al. [47] and Kasten et al. [46] assessed α RIT in tumour spheroids. Typically,
spheroids are more resistant to treatments than adherent 2D cells due to their improved replication
to solid tumours [53,54]. The increased radioresistance of the spheroids is evident in Qu et al. [47]
where the percentage of apoptotic cells was only 77% at 48 h compared to 92% for the adherent
2D cells used in Qu et al. [35]. Only minor differences were observed in the chelation of the
radioimmunoconjugates (213Bi-CHX.A”-C595 and 213Bi-cDTPA-C595) used in these two studies,
further elucidating the radioresistance of solid tumours [35,47]. Kasten et al. [46] found improved
inhibitory effects, represented by half maximal inhibitory concentration (IC50) values, in the tumour
spheroids compared to the adherent cells (26 ± 17 vs. 41 ± 14). Interestingly, when using the control
radioimmunoconjugate, cytotoxicity was greater in the adherent cells than the tumour spheroids
(120 ± 12 vs. 180 ± 150) [46]. This is likely due to the general radiation effects of the control
radioimmunoconjugate. Unfortunately, tumour spheroids were not used in any of the retrieved β
RIT studies.
Only three β RIT studies assessed cytotoxicity at an in vitro level [6,49,50]. Of these studies,
Aung et al. [50] investigated the combined efficacy of integrin-targetedβRIT and PI3k/mTOR inhibition.
The addition of PI3k/mTOR inhibition to β RIT resulted in a 90.9% reduction in plating efficiency
compared to controls at 24 h [50]. For β RIT alone, the plating efficiency was only reduced by 52.5%
compared to the controls, suggesting PI3k/mTOR inhibition can sensitise tissues to radiation [50].
Al-Ejeh et al. [6] demonstrated similar tissue sensitisation using a triple combination therapy of
epidermal growth factor receptor (EGFR)-targeted β RIT, checkpoint kinase 1 (Chk1) inhibition and
gemcitabine. In this study, the clonogenic survival of PANC-1 cells was significantly reduced when
using the triple combination therapy compared to any control treatments or the individual therapies [6].
For the remaining β RIT studies, the observed dissociation constants all demonstrated strong affinity
between the radioimmunoconjugate and the intended target.
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3.5. In Vivo Studies
In vivo studies are used to evaluate the safety, feasibility, maximum tolerated dose and
pharmacokinetics of a RIT approach in mice with human PDAC xenografts [11]. In vivo studies
provide a more reliable investigation into the efficacy and tolerability of a therapy than in vitro studies.
However, there remains difficulties in extrapolating these findings to clinical in-human trials [45].
In total, 27 of the analysed articles performed in vivo experiments, with eight studies in α RIT and
20 studies in β RIT. One article by Jiao et al. [29] performed a comparison between 213Bi and 177Lu
RIT and thus, is included in both α and β RIT components. The α RIT and β RIT in vivo studies are
summarised in Table 4. The median survival results of selected studies are presented in Figure 5.
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Figure 5. Median survival or ti to end point for in vivo studies. A, stand-alone RIT (high
and low doses) compared to control treatment (untreated or cold antibody). * p ≤ 0.01 and
** p ≤ 0.001 for high-dose RIT compared to control treatment. B, RIT in combination with other
therapeutic agents (including pre-targeting) for the treatment of PDAC compared to untreated
controls. * p < 0.05, ** p ≤ 0.001, *** p ≤ 0.0001 for combined therapy compared to control, except for
Sharkey et al. [55] and Karacay et al. [56], where p-value compares combination therapy to stand-alone
RIT. For Karacay et al. [56], the RIT only data point refers to PT-RIT only. A single representative case
is used for studies where multiple experiments were conducted.
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Table 4. In vivo studies performed using α and β RIT in PDAC.
Study Target RIC Therapies Assessed Survival Tumour Growth Tumour Uptake (%ID/g ± SD) Side Effects
A-RIT Studies
Kasten et al. [46] B7-H3 212Pb-376.96 RIT only Not investigated
Significant inhibition of tumour
growth at all RIT dose levels
compared to untreated controls
At 24 h:
14.0 ± 2.1 (RIT)
6.5 ± 0.9 (212Pb-control)
Transient weight loss
Poty et al. [57] CA19-9 225Ac-5B1 PT-RIT
Median survival (orthotopic
tumours):
67.5 days (37 kBq PT-RIT)
60.0 days (37 kBq RIT only)
32 days (18.5 kBq PT-RIT)
46 days (18.5 kBq RIT only)
28.5 days (vehicle-only control)
Not investigated
At 4 h:
4.6 ± 3.3 (PT-RIT)
15.4 ± 3.5 (conventional
RIT)
At 72 h: 29.6 ± 6.6
(PT-RIT)
31.1 ± 21.4
(conventional RIT)
All RIT groups:
Transient weight loss,
mild nephrotoxicity,
transient haemotoxicity
(more severe in
conventional RIT group
compared to PT-RIT
group)
Conventional RIT:
disseminated
intravascular
coagulation (2/10)
Jiao et al. [29] CENT1 213Bi-69-11 Comparison of
213Bi-69-11
and 177Lu-69-11
Not investigated
3.7–7.4 MBq of 213Bi-69-11:
Significant reduction in tumour
growth rate compared to
controls
Not investigated Transient haemotoxicity
Milenic et al. [58] HER2 213Bi-Herceptin RIT only
Median survival:
15 days (untreated controls)2
2 days (213Bi-control)
26 days (18.5 MBq RIT)
28 days (37 MBq RIT)
26 days (74 MBq RIT)
Not investigated in PDAC
xenografts
111In-Herceptin
24 h: 19.47 ± 3.04
48 h: 31.00 ± 8.92
72 h: 34.00 ± 10.15
120 h: 29.89 ± 3.96
168 h: 15.34 ± 5.14
Increasing weight loss
with dose
Bryan et al. [59] ssDNA andRNA
213Bi-chTNT3
RIT compared to gemcitabine
and cisplatin
Survival:
100% at day 65 (RIT, cold chTNT3
and untreated)
40% at day 65 (gemcitabine)
0% at day 15 (cisplatin)
Significant reduction in tumour
size for RIT and gemcitabine
compared to controls
Ratio of sum of pixels in
tumour region to sum of
pixels in internal organs:
1 h: 0.18
2 h: 0.22
24 h: 0.72
48 h: 0.68
No RIT-related side
effects
Qu et al. [37] uPA/uPAR 213Bi-PAI2
Comparing local and
systemic RIT injections
Local injection
Time to end point:
35 days (cold PAI2)
>84 days (≥111 MBq/kg RIT)
Systemic injection
Time to end point:
35 days (cold PAI2)
50 days (111 MBq/kg RIT)
66 days (222 MBq/kg RIT)
Local injection
Tumour growth in:
0/5 tumours (222 MBq/kg RIT)
3/5 tumours (111 MBq/kg RIT)
5/5 tumours (cold PAI2)
Systemic injection
Tumour growth in:
3/5 tumours (222 MBq/kg RIT)
5/5 tumours (111 MBq/kg RIT)
5/5 tumours (cold PAI2)
Not investigated Not reported
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Table 4. Cont.
Study Target RIC Therapies Assessed Survival Tumour Growth Tumour Uptake (%ID/g ± SD) Side Effects
Song et al. [60] uPA/uPAR 213Bi-PAI2 RIT only
Time to end point:
175 days (470 MBq/kg RIT)
162 days (590 MBq/kg RIT)
Did not reach end-point (350
MBq/kg RIT and control groups)
Not investigated Not investigated
Body weight loss with
increasing dose. Decline
in renal function.
Qu et al. [47] MUC1 213Bi-C595
Comparing local and
systemic RIT injections
Local injection
Time to end point:
42 ± 7 days (cold C595)
74 ± 3 days (213Bi-control)
77 days (1.85 MBq RIT)
>112 days (3.7–7.4 MBq RIT)
Systemic injection
42 days (cold C595)
56 days (213Bi-control)
>112 days (≥ 111 MBq/kg RIT)
Local injection
Tumour growth in:
0/5 tumours (3.7–7.4 MBq RIT)
1/5 tumours (1.85 MBq RIT)
5/5 tumours (cold C595 and
213Bi-control)
Systemic injection
Tumour growth in:
0/5 tumours (≥222 MBq/kg RIT)
2/5 tumours (111 MBq/kg RIT)
5/5 tumours (cold C595 and
213Bi-control)
Not investigated Transient weight loss
Jiao et al. [29] CENT1 177Lu-69-11 Comparison of
213Bi-69-11
and 177Lu-69-11
Not investigated
177Lu-69-11: No significant
reduction in tumour growth
compared to control treatments
Clear localisation of RIC
in tumour at 24 h Transient haemotoxicity
Houghton et al.
[61] CA19-9
177Lu-DOTA-PEG7-Tz PT-RIT using 5B1-TCO Not investigated
Tumour doubling time was
significantly increased in 44.4
MBq PT-RIT compared to
controls and 14.8 MBq PT-RIT.
Tumour volume was reduced in
44.4 and 29.6 MBq PT-RIT
compared to controls.
At 120 h:
16.8 ± 3.87 (PT-RIT) No side effects observed
Sharkey et al. [55] MUC1 90Y-hPAM4
Combined RIT and
antibody-drug conjugate
(ADC) (hRS7–SN-38)
Median time to progression:
4.3 weeks (untreated)
9.75 weeks (ADC only)
13 weeks (2.78 MBq RIT only)
>21 weeks (Combined therapy and
4.8 MBq RIT only)
Tumour-free mice at 21 weeks:
0/9 (untreated control)
1/10 (ADC only)
1/10 (2.8 MBq RIT only)
5/10 (4.8 MBq RIT only)
4/10 (Combined therapy using
2.8 MBq RIT)
9/10 (Combined therapy using
4.8MBq RIT)
At 48 h:
48.4 ± 16.4 Transient weight loss
B-RIT Studies
Aung et al. [62] Integrin α6β4 90Y-ITGA6B4 Single and double RIT cycles
Not calculated—all mice
euthanised at day 27
Growth rates significantly
reduced in single and double
RIT cycles compared to controls
Not investigated
Increasing
haemotoxicity with RIT
activity
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Table 4. Cont.
Study Target RIC Therapies Assessed Survival Tumour Growth Tumour Uptake (%ID/g ± SD) Side Effects
Aung et al. [50] Integrin α6β4 90Y-ITGA6B4
Combined RIT and
PI3K/mTOR inhibitor
(BEZ235)
Not investigated
Compared to controls, tumour
growth significantly delayed
for:
58 days (2.8 MBq RIT only)
23 days (BEZ235 only)
Compared to RIT only, tumour
growth significantly delayed for
27 days for combined therapy
Compared to BEZ235 only,
tumour growth significantly
delayed for 41 days for
combined therapy.
Not investigated No side effects observed
Aghevlian et al.
[63] EGFR
177Lu- panitumumab RIT only Not investigated Not investigated
At 72 h:
6.9 ± 1.3 (111In-MCP-
panitumumab)
6.6 ± 3.3 (111In-DOTA-
panitumumab)
1.9 ± 0.3
(111In-DOTA-control)
5.4 ± 0.3
(111In-MCP-control)
In 100-fold excess of
panitumumab:
0.02 ± 0.00 (111In-MCP-
panitumumab)
0.06 ± 0.02 (111In-DOTA-
panitumumab)
Not investigated
Aghevlian et al.
[49] EGFR
177Lu-panitumumab RIT only Not investigated
Tumour growth index at 33
days (mean ± SEM):
2.5 ± 0.3 (RIT)
4.0 ± 0.7 (Control RIC)
6.1 ± 1.1 (cold panitumumab)
5.8 ± 0.5 (untreated)
Absorbed tumour dose
for 6 Mbq of RIC:
12.33 ± 0.86 Gy
No significant effects
over 14 days
Al-Ejeh et al. [6] EGFR 177Lu-anti EGFR
Combined RIT, gemcitabine
and Chk1 inhibition (triple
therapy)
Not investigated
Tumour growth rate of all triple
therapy dose combinations was
significantly less than combined
gemcitabine and Chk1
inhibition.
Complete tumour regression in
triple therapy.
Not investigated
Weight loss with high
doses of gemcitabine or
RIT
Sugyo et al. [48] CD147 90Y-059-053
Combined RIT and
gemcitabine
Survival at day 42:
0% (untreated, cold CD147, 0.925
and 1.85 MBq RIT)
0% and 20% (3.7 MBq RIT in two
experiments)
40% (Combined therapy)
Significant suppression of
tumour growth in 3.7 MBq RIT
and combined therapy groups
compared to untreated and
gemcitabine only groups
111In-059-053
30 min: 1.04 ± 0.16
24 h: 9.23 ± 0.67
48 h: 16.13 ± 0.92
96 h: 16.78 ± 2.61
168 h: 14.98 ± 1.63
Weight loss, diarrhea
and decreasing activity
with multiple cycles
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Table 4. Cont.
Study Target RIC Therapies Assessed Survival Tumour Growth Tumour Uptake (%ID/g ± SD) Side Effects
Sabbah et al. [30] Ferritin
90Y and 111In-labelled
Bz-DTPA-AMB8LK,
Bz-CHX-AU-DTPA-AMB8LK
and Bz-DOTA-AMB8LK
RIT only—comparing
different conjugates Not investigated Not investigated
90Y-DTPA-AMB8LK:
24 h: 14.0 ± 7.5
48 h: 18.6 ± 1.9
120 h: 16.2 ± 2.9
90Y-DOTA-AMB8LK:
24 h: 14.1 ± 1.2
48 h: 12.9 ± 2.3
120 h: 11.2 ± 4.5
Not investigated
Vervoort et al. [32] Integrin avß5 131I-14C5 RIT only Not investigated Not investigated
131I-14C5
1 h: 3.63 ± 0.50
24 h: 11.22 ± 3.31
48 h: 12.16 ± 1.03
72 h: 8.45 ± 0.57
168 h: 6.91 ± 1.84
Not investigated
Al-Ejeh et al. [64]
Intracellular
La
ribonucleoprotein
90Y-DOTA-DAB4
Combination RIT,
gemcitabine and
cisplatin
Median survival
31 days (2.40 MBq RIT only)
47 days (Combined therapy)
24 days (untreated control)
Tumour doubling time (days ± SEM):
4.44 ± 0.02 (control)
5.87 ± 0.04 (RIT only)
4.88 ± 0.01 (chemotherapy only)
8.53 ± 0.02 (combined therapy)
Not investigated in
PDAC model
Not investigated in
PDAC model
Sugyo et al. [51] Transferrin 90Y-TSP-A01 RIT only Not investigated
BxPC-3 tumours: 1.85 and 3.7 MBq RIT
significantly delayed tumour growth
compared to unlabelled A01. No
significant difference in tumour volume
between 0.74 MBq RIT and unlabelled
A01.
MIAPaCa-2: Tumour volumes in 1.85
MBq and 3.7 MBq RIT groups were
reduced to 20%. Complete resolution of
tumours treated with 3.7 MBq RIT by 6
weeks.
Peak 111In-TSP-A01
uptake:
37.5 ± 5.3 at 24 h
(MIAPaCa-2)
27.0 ± 10.7 at 96 h
(BxPC-3)
Transient decrease in
body weight
Baranowska-Kortylewicz
et al. [65] PDGFR
131I-CC49
Combined RIT and
PDGFR inhibitor
(imatinib)
Not investigated
Tumour doubling time (days):
12.86 ± 0.19 (RIT only)
26.06 ± 1.47 (combined therapy)
13.03 ± 0.27 (imatinib only)
9.05 ± 0.05 (untreated control)
At 120 h:
6.06 ± 1.76 (RIC only)
9.03 ± 1.59 (RIC and
imatinib)
No side effects
Cardillo et al. [66] MUC1 131I-PAM4 and 90Y-PAM4
Comparing RICs as
stand-alone treatments
Median survival:
6 weeks (untreated)
13 weeks (13 MBq 131I RIT)
12 weeks (19 MBq 131I RIT)
17.5 weeks (26 MBq 131I RIT)
16 weeks (4.8 MBq 90Y RIT)
>26 weeks (≥6.5 MBq 90Y RIT)
Mean size of tumours at nadir (cm3):
N/A (untreated and ≤19 MBq 131I RIT as
tumours never regressed)
0.61 ± 0.24 (26 MBq 131I RIT at 7 weeks)
0.78 ± 0.61 (4.8 MBq 90Y RIT at 6 weeks)
0.33 ± 0.40 (6.5 MBq 90Y RIT at 7 weeks)
0.10 ± 0.07 (8.1 MBq 90Y RIT at 9 weeks)
0.19 ± 0.13 (9.6 MBq 90Y RIT at 10 weeks)
Radiation dose
estimates to tumour
(cGy):
8559 (26 MBq 131I RIT)
8068 (9.6 MBq 90Y RIT)
Weight loss
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Table 4. Cont.
Study Target RIC Therapies Assessed Survival Tumour Growth Tumour Uptake (%ID/g ± SD) Side Effects
Gold et al. [67] MUC1 90Y-PAM4 Single RIT Not investigated Not investigated 96 h: 39.5 ± 16.4 Not investigated
Cardillo et al. [68] MUC1 131I-PAM4
Combined RIT and
gemcitabine
Median survival:
6 weeks (3.7 MBq RIT only)
10 weeks (combined therapy using
3.7 MBq RIT)
9 weeks (combined therapy using
3.7 MBq 131I control)
13 weeks (7.4 MBq RIT only)
13 weeks (combined therapy using
7.4 MBq RIT)
10 weeks (combined therapy using
7.4 MBq control RIC)
6 weeks (untreated controls)
5 weeks (gemcitabine only)
Normalised tumour growth at week 4:
3.91 ± 2.54 (3.7 MBq RIT only)
1.69 ± 1.26 (combined therapy using 3.7
MBq RIT)
1.45 ± 1.05 (combined therapy using
3.7MBq 131I control)
1.58 ± 0.84 (7.4 MBq RIT only)
1.13 ± 0.50 (combined therapy using 7.4
MBq RIT)
1.92 ± 1.02 (combined therapy using 7.4
MBq control RIC)
4.16 ± 0.89 (untreated control)
4.35 ± 1.80 (gemcitabine only)
131I-PAM4:
24 h: 12.08 ± 6.85
72 h: 11.08 ± 5.56
168 h: 8.04 ± 6.13
336 h: 4.00 ± 2.80
131I-PAM4 and
gemcitabine:
24 h: 12.21 ± 5.73
72 h: 14.29 ± 7.31
168 h: 8.39 ± 6.50
336 h: 2.52 ± 2.30
Weight loss
Gold et al. [69] MUC1 90Y-PAM4
Combined RIT and
gemcitabine
Median survival
16 weeks (RIT only)
24 weeks (combined therapy)
11 weeks (combined therapy with
90Y control)
8 weeks (90Y control only)
10 weeks (gemcitabine only)
8.5 weeks (untreated controls)
Tumour response
Week 10:
1/9 PR (RIT only)
1/9 CR, 3/9 PR, 2/9 SD (combined therapy)
Disease progression in all other groups
Week 26:
4/9 CR (combined therapy)
111In-cPAM4:
24 h: 18.65 ± 2.93
96 h: 26.93 ± 11.81
168 h: 18.05 ± 11.02
111In-cPAM4 and
gemcitabine:
24 h: 21.79 ± 4.55
96 h: 36.70 ± 9.58
168 h: 25.47 ± 10.35
Weight loss and
transient reduction
in white blood cell
counts
Gold et al. [70] MUC1 90Y-PAM4
Combined RIT and
gemcitabine
Median survival
12 weeks (single cycle combined
therapy)
9 weeks (single RIT only)
7 weeks (single cycle combined 90Y
control)
4 weeks (gemcitabine only) 6 weeks
(untreated controls)
21 weeks (double cycle combined
therapy)
16 weeks (double RIT only)
10 weeks (double cycle combined
90Y control)
Tumour response:
1/13 PR, 8/13 SD (single cycle combined
therapy)
7/12 SD (single RIT only)
1/8 PR (90Y control only)
1/10 CR (single cycle combined 90Y
control therapy)
1/13 SD (double cycle 1.85 MBq 90Y
control)
3/13 SD, 1/13 PR (double cycle combined
1.85 MBq 90Y control therapy)
3/12 SD, 4/12 PR (double cycle 3.7 MBq
RIT)
4/12 SD, 7/12 PR (double cycle combined
3.7 MBq RIT)
Not investigated Transient weightloss
Karacay et al. [56] MUC1 PT-RIT:
90Y-IMP-288
RIT only: 90Y-PAM4
Combined TF10 PT-RIT
and gemcitabine
Time to progression
16.3 weeks (9.25 MBq PT-RIT)
5.4 week (untreated controls)
>30 weeks (18.5 MBq PT-RIT and
5.55 MBq 90Y RIT only)
4.8 weeks (9.25MBq PT-RIT)
18.1 weeks (combined PT-RIT and
gemcitabine)
Tumour-free mice at week 19:
8/10 (18.5 MBq PT-RIT)
3/10 (9.25 MBq PT-RIT)
8/9 (5.55 MBq RIT only)
0/10 (untreated controls)
Not investigated
Transient decrease in
white blood cell
counts, diarrhea
(1/11). No
nephrotoxicity
observed.
RIC: radioimmunoconjugate, %ID/g: percentage of injected dose/gram, SD: standard deviation, PT: pre-targeted, CIT: chemoimmunotherapy, PI3K/mTOR:
phosphatidylinositol-3-kinase/mammalian target of rapamycin, MCP: metal chelating polymer, SEM: standard error measurement, Chk1: checkpoint kinase 1, PR: partial response, SD:
stable disease, CR: complete resolution.
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Many of the in vivo studies demonstrated a significant improvement in survival in the mice who
received α or β RIT compared to the control treatments (untreated or unlabelled antibody). Typically,
survival improved with higher RIT doses, multiple treatment cycles and the use of a combination therapy
approach when delivered within tolerable limits. As an emerging approach, α RIT was primarily
assessed as a stand-alone therapy for PDAC, with only Poty et al. [57] evaluating the influence of a
pre-targeted approach. In comparison, few in vivo studies focused directly on investigating a single
β RIT cycle, with the majority assessing different administration routes, pre-targeting and various
combination therapies including the addition of chemotherapy and inhibitors. These variations,
along with differences in tumour size, location, observation period and activity administered, limit
comparison between the effectiveness of α and β RIT in animals, with both approaches demonstrating
value in treating PDAC.
In the only study to compare α and β RIT, Jiao et al. [29] indicate that 213Bi α RIT is superior to
177Lu β RIT for treating CENT-1 positive PDAC. Jiao et al. [29] found 213Bi-69-11 was more effective at
suppressing tumour growth compared to 177Lu-69-11, with tumour size increasing by only 10-fold
in the α RIT group compared to approximately 30-fold in the β RIT group. Additionally, 213Bi was
found to be as tolerable as 177Lu, with transient haemotoxicity the only side effect observed [29].
Whilst further work is needed to harness the full potential of 213Bi-69-11, Jiao et al. [29] effectively
demonstrates the superiority of α RIT in controlling PDAC tumour growth without compromising
on safety and tolerability. Ideally, more studies which directly compare α and β RIT models are
needed. However, the variety of radionuclides available for such studies is limited due to the varying
chelation requirements of different radionuclides, which can affect the conjugate kinetics and accuracy
of the comparison.
Whilst stand-alone RIT had superior therapeutic efficacy compared to most control treatments,
RIT in combination with other therapeutic agents further improved tumour control. The most
widely investigated combination therapy was gemcitabine and β RIT. However, inhibitors and
pre-targeting were also assessed. Between the combined gemcitabine and β RIT studies, Gold et al. [69]
demonstrated the greatest improvement in survival in the combination therapy compared to stand-alone
RIT groups (24 weeks vs. 16 weeks). However, the same RIT activity of 0.925 MBq (equating to
10% of the pre-determined maximum tolerated dose) was administered to mice in the combination
and stand-alone RIT groups [69]. Typically, a lower RIT dose should be administered when it is
used in combination with another toxic agent such as gemcitabine due to the synergistic effects and
potential for toxicities [71]. As stand-alone RIT has less potential for toxicities, a higher RIT dose can be
administered to achieve optimal therapeutic efficacy whilst tolerability is maintained. By prescribing
the same RIT activity for both groups, the comparison between the combination and stand-alone RIT
treatments is less clinically relevant and may affect translation into clinical studies.
Despite many studies showing positive tumour responses to α and β RIT, there remains concern
in the application of these therapies due to the associated toxicities. The primary side effects observed
in both in vivo α and β RIT studies were transient weight loss and haemotoxicities. More severe
side effects such as disseminated intravascular coagulation, diarrhea, nephrotoxicity and decreasing
activity were also observed in both RIT approaches in a limited number of animals [48,56,57,60]. For
β RIT, the presence of side effects typically increased with dose or the addition of chemotherapy to
the RIT regime. When inhibitors such as PI3k/mTOR and platelet derived growth factor receptor
(PDGFR) were administered in combination with RIT, there were no reported side effects [50,65]. As
some inhibitors are believed to have radiosensitising properties [72], there is potential to lower the
dose of RIT to reduce the level of radiation damage to normal tissues and associated toxicities, without
compromising on tumour control. Therefore, the combination of molecular pathway inhibitors and
RIT may be valuable for improving the tolerability of RIT treatments.
Nephrotoxicity was observed in some mice receiving α RIT yet not β RIT [57,60]. The effect of
α RIT on renal function is likely due to the elimination pathway of the radioimmunoconjugate and
recoiling daughter radionuclides. Several free or conjugated α-emitting radionuclides such as 213Bi
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and 225Ac-DOTA are excreted via the urinary system [73,74]. Whilst the majority of these agents are
rapidly excreted, longer term retention has been observed with some 213Bi conjugates [73]. However,
the primary safety issue of α-emitting radionuclides lies in the production of recoiling daughter
radionuclides following the chain decay of some α emitters, namely 225Ac. The recoil energy of these
daughter radionuclides is sufficient to overcome the chemical bonds of the conjugate, allowing the
radionuclide to dissociate and travel freely within the blood [75]. The most widely considered recoiling
daughter product is 213Bi which results from the decay of 225Ac. With free 213Bi known to localise
within the kidneys, it is imperative for 225Ac conjugates to be internalised with all potentially cytotoxic
daughter products to remain contained following α decay [74–76]. Clear investigations into methods
to limit kidney damage induced by α-emitting radionuclides, either due to recoiling daughter products
or general elimination, are needed to improve tolerability of α RIT.
3.6. Clinical Trials
Clinical trials provide the most reliable data regarding the efficacy and safety of a treatment
in humans. In total, there have been five clinical trials investigating β RIT in PDAC. Four of these
studies have published results from Phase I and II trials, with the fifth study, a Phase III trial, currently
unpublished. The results of these trials are summarised in Table 5 and Figure 6. At the time of searching
(August 2019), no clinical trials had been performed investigating α RIT as a treatment for PDAC.
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Table 5. Summary of clinical trials performed investigating β RIT in PDAC.
Study Target RIC Study Type Sample (n) Patient Group
Median Overall
Survival
(Months)
Tumour Responses DiseaseControl Rate Adverse Events * (Grade ≥ 3)
Sultana et al.
[77] CEA
131I-KAb201
Single RIT
comparing IV
and IA
administration
18
Locally advanced or metastatic
PDAC, with at least one tumour
site in head of pancreas. KPS ≥
70, life expectancy < 3 months.
Prior treatment allowed but not
necessary for inclusion.
5.2
No survival
difference
between IV and
IA
administrations
1/18 (5.6%) partial
responses
1/18 (5.6%) stable
disease
16/18 (88.9%)
progression
11.2%
In total, 31 therapy related adverse
events were observed.
Haemotological toxicity, 18 events;
sepsis and vomiting, two events
each; alanine aminotransferase,
anaemia, anorexia, aspartate
aminotransferase, blood alkaline
phosphatase, febrile neutropenia,
haematemesis, neutrophilia and
thrombosis, one event each.
Picozzi et al.
[78] MUC1/MUC5ac
90Y-hPAM4
Combination
with
gemcitabine
58
Metastatic PDAC, ≥ 2 prior
chemotherapy regimens with
measurable disease by CT. No
CNS metastases of single masses
≥10cm. KPS ≥ 70. Adequate
haematologic parameters.
2.7 (overall
survival for all
patients)
7.9 (multiple
cycles of
combined
therapy)
3.4 (multiple
cycles of RIT only)
2/29 (6.9%) partial
responses (combined
therapy group)
10/29 (34.5%) stable
disease (combined
therapy group)
12/29 (41.4%) stable
disease (RIT only
group)
41.4%
Thrombocytopenia, 19% of patients
(11/58); anaemia, leukopenia and
neutropenia, 7% each (4/58),
unspecified, 2% (1/58).
Ocean et al.
[79] MUC1
90Y-hPAM4
Fractionated
RIT combined
with
gemcitabine
38
Untreated adults with locally
advanced or metastatic PDAC.
KPS ≥ 70. Life expectancy > 3
months, no CNS tumours or
single tumour mass > 10cm.
Adequate haematologic
parameters.
7.7
6/38 (15.8%) partial
response
16/38 (42.1%) stable
disease
16/38 (42.1%) disease
progression
57.9% No significant therapy relatedadverse events occurred.
Gulec et al.
[80] MUC1
90Y-hPAM4 Single RIT 20
Stage III or IV PDAC. If stage III,
must have progressed after
therapy. Stage IV patients must
have had no more than one prior
chemotherapy regimen. No CNS
tumours or single mass > 10cm.
KPS ≥ 70 or ECOG ≤1. Adequate
haematological parameters.
4.3
At 4 weeks:
3/20 (15.0%) partial
response
4/20 (20.0%) stable
disease
At 4 weeks:
35.0%
Follow up: 0%
Eight therapy related adverse events
occurred consisting of seven
cytopenia events and a single
vomiting event.
ClinicalTrials.gov
[81] MUC1
90Y-hPAM4
RIT with
gemcitabine
Data not
available
Metastatic PDAC, completed at
least one prior treatment cycle,
progressed following
gemcitabine regimen, KPS ≥ 70.
No CNS tumours or single mass
> 10 cm.
No significant
improvements in
survival in
combined therapy
group compared
to gemcitabine
only group
Data not available Data notavailable Data not available.
* Includes only adverse events considered possibly treatment related. RIC: radioimmunoconjugate, IV: intravenous, IA: intraarterial, KPS: Karnofsky Performance Status, CNS: central
nervous system, ECOG: Eastern Cooperative Oncology Group.
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All β RIT trials investigated similar patient populations with stage III or IV PDAC.
Sultana et al. [77] had the lowest number of participants (n = 18) whilst Picozzi et al. [78] had the
greatest number (n = 58). The greatest variation between trials was the participants’ number of
prior treatments. Sultana et al. [77] allowed patients to have had prior treatments although it was
not necessary for study enrolment. Ocean et al. [79] recruited previously untreated patients only
whilst patients in Picozzi et al. [78] must have received at least two prior chemotherapy regimens.
In Gulec et al. [80], stage III patients were required to have had some form of initial therapy whilst
stage IV patients needed to have had only one chemotherapy regimen prior to study enrolment.
These variations in prior treatments may affect patients’ responses, particularly to combined therapies
using gemcitabine, as PDAC is known to develop resistance once exposed to a certain treatment [82].
Additionally, prior treatments such as chemotherapy can cause bone marrow suppression and increase
the likelihood of toxicities from subsequent treatments. Picozzi et al. [78] recognised the potential for
bone marrow suppression in their cohort who had previous chemotherapy and administered a lower
RIT dose to reduce dose-limiting toxicities [78].
Whilst all trials used the Response Evaluation Criteria in Solid Tumours (RECIST) to determine
disease control rate, follow-up times varied. Three of the trials determined the disease control rate based
on the patients’ best treatment responses between 1 and 3 months post-therapy [77,79,80]. In contrast,
Picozzi et al. [78] continued to monitor patients with CT scans every 7–8 weeks and calculated the
disease control rate when there was disease progression. The flexible approach of Picozzi et al. [78]
allows for a more thorough calculation. However, the longer follow-up time between scans may have
falsely extended disease control time.
Most β RIT trials investigated a MUC1-targeted approach using the 90Y-hPAM4 conjugate.
Gulec et al. [80] was the first study to investigate the efficacy and safety of stand-alone β RIT using
90Y-hPAM4. Despite an initial disease control rate of 35% at four weeks post-therapy, all patients had
disease progression by 24 weeks [80]. The addition of a gemcitabine regimen improved disease control
to 41.4% and 57.9% respectively in Picozzi et al. [78] and Ocean et al. [79]’s trials and further highlights
the potential value of combination therapies. Despite positive disease control rates, 90Y-hPAM4 RIT
with or without gemcitabine, still requires improvements to treat advanced disease and better improve
median survival. In Picozzi et al. [78], overall median survival was only 2.7 months. However, this
improved to 3.4 months for patients receiving multiple cycles of stand-alone RIT and 7.7 months for
patients receiving multiple cycles of combined RIT and gemcitabine [78]. Survival was generally better
in patients with a greater Karnofsky performance status and lower serum CA19-9 levels, indicating
the therapies are less effective in targeting more advanced disease [78]. Similar conclusions can be
drawn from Ocean et al. [79] where overall median survival was 7.7 months. Median survival was
reduced to 6.0 months for stage IV patients only whilst stage III patients experienced median survival
of 19.6 months. This further demonstrates both the need for earlier detection of PDAC and improved
therapeutic measures to target metastatic dissemination observed in stage IV disease. An unpublished
Phase III trial [81] investigating 90Y-hPAM4 β RIT combined with gemcitabine also failed to improve
median survival. At interim analysis, the trial was prematurely terminated due to a lack of overall
improvement in survival in the combined therapy group compared to the gemcitabine-only control
group [81]. Currently, data from the phase III trial is unpublished preventing further analysis.
Ocean et al. [79] was the only trial to investigate a fractionated RIT approach in combination with
gemcitabine. Fractionated RIT can increase the radiosensitivity of the tumour cells as per the 5 Rs of
radiobiology: reoxygenation, repair, radiosensitivity, redistribution and repopulation. Fractionation
increases oxygenation (↑ radiosensitivity), reduces time for cells to repair damage from previous
radiation fractions (↑ radiosensitivity), allows cells to enter different phases of the cell cycle which
varies in radiosensitivity and targets cells which repopulate from unkilled tumour cells. Given Ocean
et al. [79] had the greatest disease control rate of 57.9% between the trials, fractionation many have
value in the delivery of combination RIT, with the practicality of this approach likely to improve at
higher RIT doses [83].
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Sultana et al. [77] was the only trial to compare therapeutic efficacy between intravenous and
intraarterial injections. It was hypothesised that the intraarterial injection of 131I-KAb201 would result
in greater therapeutic efficacy and reduced toxicity due to its higher potential drug concentration at
the tumours [77]. However, overall median survival was 5.2 months, with no significant difference
between the administration routes [77]. Regardless, investigations into different administration routes
should be more commonly performed for RIT to optimise clinical regimens.
Overall, haematological toxicities such as anaemia, thrombocytopenia, leukopenia and neutropenia
were the most commonly reported adverse events across the clinical trials. The high prevalence of
cytopenia within these trials is typical of radiation and chemotherapies, given myelosuppression
is often the dose-limiting toxicity of these treatments [84]. Other common adverse events included
fatigue, nausea, vomiting and a series of gastrointestinal disturbances. Whilst all trials used the
relevant National Cancer Institute Common Toxicity Criteria available at the time of study, there were
discrepancies in reporting the grades of adverse events which has prevented in-depth comparison
between therapy side effects. Gulec et al. [80] reported the highest percentage of patients experiencing
serious treatment-related adverse events with 55%. In comparison, approximately 40% of patients
experienced serious adverse events in Ocean et al. [79]’s study whilst only 10% of patients had serious
treatment-related adverse events in Picozzi et al. [78]. The lower incidence of serious adverse events in
Picozzi et al. [78] may be related to the lower RIT dose delivered (6.5 mCi/m2) compared to the other
trials (6.5–15.0 mCi/m2 and 15.0–25.0 mCi/m2, respectively for Ocean et al. [79] and Gulec et al. [80]).
Sultana et al. [77] reported 31 potentially treatment-related adverse events.
At study enrolment, all patients had either an Eastern Cooperative Oncology Group (ECOG)
performance status of ≤1 or a Karnofsky performance status ≥70%, except for one patient in
Ocean et al. [79] who had an ECOG of 2 [77–80]. Unfortunately, no trial presented follow-up
performance status or quality of life data. This has prevented evaluations into the potential symptomatic
relief provided by RIT.
3.7. Limitations of Review
The data presented throughout the retrieved literature was highly heterogeneous in nature. At
the in vitro level, differences in study objective, pancreatic cancer cells/tissues and radionuclide used
amongst other factors limited our ability to compare the feasibility of α and β RIT for the treatment
of PDAC. Similarly, in vivo studies varied in terms of tumour size, location, activity administered
and observation period. This prevented in-depth assessments into the impact of these factors on
disease control and tolerability, particularly between stand-alone and combination therapies. Finally,
whilst several of the clinical trials included in this review investigated 90Y-hPAM4, limited reporting
regarding the grades of the adverse events and overall efficacy of the treatments weakened the review.
Despite systematically retrieving the literature in this review, the variation in the factors described
above prevented a systematic analysis of the data, ultimately limiting the comparison between α and
β RIT as a treatment for PDAC.
3.8. Overall Discussion
RIT is an evolving therapy with potential to improve the outcomes of several low-survival cancers
including PDAC. Through the specific targeting of cancerous cells only, RIT can spare normal tissues to
provide a high level of tumour control without compromising on patient safety and tolerability. In the
current state, RIT is likely to be most valuable as a neoadjuvant or adjuvant therapy to debulk tumour
size and reduce the likelihood of disease recurrence in PDAC. The short range and high LET of the α
particle suggest α RIT is more suitable to target undetectable or micro-metastases which often lead to
disease recurrence [3]. In comparison, β RIT may be useful for debulking the primary tumour given its
longer range and improved cross-fire effect.
Whilst RIT alone can suppress tumour growth, RIT in combination with other therapeutic agents
is likely to have the most clinical benefit for patients with PDAC. Combination therapies can have
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synergistic effects to increase stromal permeability and cytotoxicity. Given the cellular heterogeneity
of PDAC, combination therapies can better target all cancerous cells by overcoming the intrinsic
resistance of some PDAC treatments. With the development of these combination therapies comes a
need to establish the optimal treatment strategy due to the higher toxicity associated with combined
treatments. This will include determining the most effective administration route, cycle length, dosage
and timing of administration to achieve optimal tumour control and tolerability. Whilst the 5 Rs of
radiobiology are largely applied to traditional radiation therapy, they may also be applied to RIT to
enhance treatment efficacy.
Gemcitabine and β RIT was the most widely investigated combination treatment in this review.
Gemcitabine, a chemotherapy agent, acts as a radiosensitiser whilst also providing its own therapeutic
effect [71]. At a preclinical level, β RIT and gemcitabine provided superior tumour control compared
to stand-alone β RIT, with acceptable side effects. In clinical trials, this combination also demonstrated
positive disease control rates of 41.4%–57.9%. However, improvements in survival were marginal,
particularly for advanced disease [78,79,81]. The poor translation to clinical trials may be due to the
intrinsic limitations of preclinical studies whereby they are unable to fully evaluate the potential
of targeting bulky tumours as well as micro-metastases. The inherent toxicities of combining both
treatment approaches may have also contributed to the poor survival improvements, as the maximal
tolerated doses of both approaches is limited when treatments are used in combination [85].
Advanced PDAC characterised by wide-spread metastatic dissemination may be better controlled
by α RIT than β RIT. The current paucity in the literature regarding clinical α RIT studies for PDAC
limits comparison. The primary concern regarding α RIT is the potential for nephrotoxicity due
to the elimination pathway of the radioimmunoconjugates and localisation of recoiling daughter
products [57,60]. The use of nano-carriers, fast tumour uptake of the radioimmunoconjugate and direct
tumour administration may be beneficial for reducing the potential toxicity of α RIT [75]. Establishing
the kinetics of the radioimmunoconjugate and daughter radionuclides through internalisation
experiments at the in vitro level may also assist in translation to clinical studies. To comprehensively
evaluate the potential of α RIT for targeting advanced PDAC, clinical studies are urgently needed.
Despite stand-alone α RIT demonstrating considerable therapeutic potential, a combined or
pre-targeted approach may be superior if normal tissue toxicities can be appropriately controlled. If
α RIT is to follow a similar path to β RIT, gemcitabine is a potential secondary agent for combined
therapy. However, the added effect of gemcitabine to an α RIT regimen may be less pronounced than
that observed in combined β RIT studies due to the superior cytotoxicity of the α particle. Further
challenges will arise in limiting the normal tissue toxicities associated with combining gemcitabine
and α RIT given both agents are already considerably cytotoxic. Alternatively, the addition of
molecular pathway inhibitors or pre-targeting may improve cytotoxicity without compromising
on tolerability. In this review, the side effects observed in pre-targeted α and β RIT or β RIT in
combination with inhibitors, were no worse than those observed in RIT alone, whilst tumour control
improved. Largely, these findings are due to the mechanisms involved in pre-targeting and inhibition.
In pre-targeting, unlabelled antibodies are initially injected to bind with circulating antigens in
the blood. The radioimmunoconjugate is then injected and has increased binding to the tumour
cells [43]. The process of pre-targeting improves blood clearance and tumour localisation of the
radioimmunoconjugate to minimise radiation damage to normal tissues. Pre-targeting has already
shown value in reducing the incidence of nephrotoxicity in α RIT due to the fast uptake of the
radioimmunoconjugate [57]. On the other hand, some inhibitors act as radiosensitisers to block relevant
tumour signalling processes [50]. Inhibitors are less toxic to normal tissues than gemcitabine and may
be better suited for combination therapies with α RIT than more toxic agents. Whilst pre-targeting and
inhibition has shown value in animal models, clinical trials are needed to fully evaluate the potential
of these therapies in a human population.
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4. Conclusions
Optimising RIT for the treatment of PDAC is an ongoing challenge, particularly for targeting
advanced disease. There is a need to improve clinical translation by balancing tumour control with
tolerability and improvements in patient survival. Limited clinical studies in both α and β RIT have
so far prevented the ability to identify and optimise an effective RIT treatment strategy. RIT will
continue to not succeed in the clinic for the treatment of PDAC unless future studies invest in assessing
all aspects of the treatment strategy and not just tumour control alone. Further developments and
optimisation of therapy combinations are urgently needed to harness the full potential of RIT for
PDAC, especially for α RIT.
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Appendix A
Table A1. MEDLINE® Search Strategy used to retrieve articles included within this review.
Search Terms
1 Pancreatic Neoplasms/
2 Carcinoma, Pancreatic Ductal/
3
(Pancrea * adj3 (neoplasm * or cancer * or carcinoma * or tumo?r *)).mp. [mp = title, abstract,
original title, name of substance word, subject heading word, floating sub-heading word, keyword
heading word, organism supplementary concept word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier, synonyms]
4 1 or 2 or 3
5 A Particles/tu [Therapeutic Use]
6 Radioimmunotherapy/
7 B particles/tu [Therapeutic use]
8
(immuno?radio?therap * or radio?immuno?therap * or α therap * or α particle? therap * or α
radio?therap * or β therap * or β particle? therap * or β particle? radio?therap * or β radio?therap *
or radio?labelled anti?bod * or α immuno?conjugat * or β immuno?conjugat * or
radio?immuno?conjugat *).mp. [mp = title, abstract, original title, name of substance word, subject
heading word, floating sub-heading word, keyword heading word, organism supplementary
concept word, protocol supplementary concept word, rare disease supplementary concept word,
unique identifier, synonyms]
9 5 or 6 or 7 or 8
10 4 or 9
11 Limit 10 to (English language and year = “2000–current”)
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